XML 109 R97.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details) - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Other intangible assets    
Disclosure of operating segments [Line Items]    
Impairment Loss on Intangible Asset Other Than Goodwill € 210  
Net income attributable to non-controlling interests 25 € 17 [1]
Fair value remeasurement of contingent consideration (61) (66) [1]
Restructuring costs and similar items [2] (430) (1,060) [1]
Other gains and losses, and litigation (57) (450) [1]
Operating income 3,759 2,768 [3]
Financial expenses (361) (583) [3],[4]
Financial income 184 277 [3],[4]
Income before tax and investments accounted for using the equity method 3,582 2,462 [1],[5]
Impairment loss on other intangible assets 210 (371) [1]
Biopharma Segment [Member]    
Disclosure of operating segments [Line Items]    
Business operating income 5,347 4,916 [6]
Share of profit (loss) of associates and joint ventures accounted for using equity method 77 66 [6]
Net income attributable to non-controlling interests (8) (6) [6]
Operating segments    
Disclosure of operating segments [Line Items]    
Business operating income 5,363 4,938 [3]
Material reconciling items    
Disclosure of operating segments [Line Items]    
Share of profit (loss) of associates and joint ventures accounted for using equity method [7] (77) (66) [3]
Net income attributable to non-controlling interests [8] 8 6 [3]
Amortization and impairment of intangible assets [9] (987) (527) [3]
Fair value remeasurement of contingent consideration (61) (66) [3]
Expense arising from the impact of acquisitions on inventories [10] 0 (7) [3]
Restructuring costs and similar items [11] (430) (1,060) [3]
Other gains and losses, and litigation [12] € (57) € (450) [3]
[1] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[2]
(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[4] Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[5]
(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[6] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[7] Joint ventures and associates with which Sanofi has entered into a strategic alliance.
[8] Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests.
[9] The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of €210 million in the first half of 2025 linked to research and development projects. .As of June 30, 2024, this line includes a net reversal of impairment losses amounting to €371 million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights.
[10] This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.
[11] See Note B.16.
[12] See Note B.17